I just did a quick scan of Zenith Epigenetics Financials recently posted on Sedar
The Management Discussion and financials are perplexing
I just do not understand how the Chairman of the Board could float a value of $500mm in a recent presentation without justification
No valuation of Royalty Preferred shares in the financials means that the royalties are not reasonably determinable and the revenue stream at this point in time is not probable.
Hopefully the still awaited ZEN papers will unmask the mystery -
Chicagoest